Literature DB >> 6402921

Rh mosaicism and aberrant MNSs antigen expression in a patient with chronic myelogenous leukemia.

A W Bracey, M H McGinniss, R M Levine, J Whang-Peng.   

Abstract

This is, to our knowledge, the first report of combined Rh and MNSs antigen alteration in a leukemic patient. Red blood cells of a chronic myelogenous leukemia patient demonstrated mixed field reactions with anti-Rho (D) reagents in August 1980. Earlier tests indicated he was Rho (D) positive in 1967, but Rho (D) and Du negative from 1973 to 1980. Titration studies with anti-hr' (c) and anti-hr" (e) indicated depressed expression, and there was also very weak s expression. One hundred per cent of cells studied from 1967 to 1980 were Philadelphia chromosome (Ph1) positive. No abnormalities in chromosomes associated with the Rh or MNSs blood groups 1 and 4, respectively, were noted. Phenotypes from August 1980 through September 1981 revealed normalization of red blood cell antigen status with an increase of Rho (D) positive cells from 35% to 100%. Chromosomal studies in October, 1980 and June, 1981 revealed Ph1 mosaicism with 25 and 75% Ph1 negative cells, respectively. These findings suggest that normalization of previously altered red blood cell antigen expression may reflect resurgence of normal stem cell lines.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6402921     DOI: 10.1093/ajcp/79.3.397

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

Review 1.  Frameshift variations in the RHD coding sequence: Molecular mechanisms permitting protein expression.

Authors:  Willy A Flegel; Kshitij Srivastava
Journal:  Transfusion       Date:  2020-10-09       Impact factor: 3.337

2.  Somatic mosaicisms of chromosome 1 at two different stages of ontogenetic development detected by Rh blood group discrepancies.

Authors:  Eva-Maria Dauber; Wolfgang R Mayr; Hein Hustinx; Marlies Schönbacher; Holger Budde; Tobias J Legler; Margit König; Oskar A Haas; Gerhard Fritsch; Günther F Körmöczi
Journal:  Haematologica       Date:  2018-09-20       Impact factor: 9.941

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.